PMID- 36213540
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221011
IS  - 2211-3835 (Print)
IS  - 2211-3843 (Electronic)
IS  - 2211-3835 (Linking)
VI  - 12
IP  - 10
DP  - 2022 Oct
TI  - Autophagy and beyond: Unraveling the complexity of UNC-51-like kinase 1 (ULK1) 
      from biological functions to therapeutic implications.
PG  - 3743-3782
LID - 10.1016/j.apsb.2022.06.004 [doi]
AB  - UNC-51-like kinase 1 (ULK1), as a serine/threonine kinase, is an autophagic 
      initiator in mammals and a homologous protein of autophagy related protein (Atg) 
      1 in yeast and of UNC-51 in Caenorhabditis elegans. ULK1 is well-known for 
      autophagy activation, which is evolutionarily conserved in protein transport and 
      indispensable to maintain cell homeostasis. As the direct target of energy and 
      nutrition-sensing kinase, ULK1 may contribute to the distribution and utilization 
      of cellular resources in response to metabolism and is closely associated with 
      multiple pathophysiological processes. Moreover, ULK1 has been widely reported to 
      play a crucial role in human diseases, including cancer, neurodegenerative 
      diseases, cardiovascular disease, and infections, and subsequently targeted 
      small-molecule inhibitors or activators are also demonstrated. Interestingly, the 
      non-autophagy function of ULK1 has been emerging, indicating that 
      non-autophagy-relevant ULK1 signaling network is also linked with diseases under 
      some specific contexts. Therefore, in this review, we summarized the structure 
      and functions of ULK1 as an autophagic initiator, with a focus on some new 
      approaches, and further elucidated the key roles of ULK1 in autophagy and 
      non-autophagy. Additionally, we also discussed the relationships between ULK1 and 
      human diseases, as well as illustrated a rapid progress for better understanding 
      of the discovery of more candidate small-molecule drugs targeting ULK1, which 
      will provide a clue on novel ULK1-targeted therapeutics in the future.
CI  - (c) 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, 
      Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
FAU - Zou, Ling
AU  - Zou L
AD  - School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, 
      Shenzhen 518060, China.
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University, Chengdu 610041, China.
FAU - Liao, Minru
AU  - Liao M
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University, Chengdu 610041, China.
FAU - Zhen, Yongqi
AU  - Zhen Y
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University, Chengdu 610041, China.
FAU - Zhu, Shiou
AU  - Zhu S
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University, Chengdu 610041, China.
FAU - Chen, Xiya
AU  - Chen X
AD  - School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, 
      Shenzhen 518060, China.
FAU - Zhang, Jin
AU  - Zhang J
AD  - School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, 
      Shenzhen 518060, China.
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University, Chengdu 610041, China.
FAU - Hao, Yue
AU  - Hao Y
AD  - School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, 
      Shenzhen 518060, China.
FAU - Liu, Bo
AU  - Liu B
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University, Chengdu 610041, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220611
PL  - Netherlands
TA  - Acta Pharm Sin B
JT  - Acta pharmaceutica Sinica. B
JID - 101600560
PMC - PMC9532564
OTO - NOTNLM
OT  - Autophagy
OT  - Biological function
OT  - Human diseases
OT  - Non-autophagy
OT  - Small-molecule drug
OT  - ULK1-targeted therapy
OT  - UNC-51-like kinase 1 (ULK1)
COIS- The authors have no conflicts of interest to declare.
EDAT- 2022/10/11 06:00
MHDA- 2022/10/11 06:01
PMCR- 2022/06/11
CRDT- 2022/10/10 04:33
PHST- 2022/02/17 00:00 [received]
PHST- 2022/05/27 00:00 [revised]
PHST- 2022/06/02 00:00 [accepted]
PHST- 2022/10/10 04:33 [entrez]
PHST- 2022/10/11 06:00 [pubmed]
PHST- 2022/10/11 06:01 [medline]
PHST- 2022/06/11 00:00 [pmc-release]
AID - S2211-3835(22)00270-2 [pii]
AID - 10.1016/j.apsb.2022.06.004 [doi]
PST - ppublish
SO  - Acta Pharm Sin B. 2022 Oct;12(10):3743-3782. doi: 10.1016/j.apsb.2022.06.004. 
      Epub 2022 Jun 11.